RxDoctor Payments Data

Mark Kieran

Pediatric Hematology-Oncology · Boston, MANPI 1790747236

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,399 of the $2,412 with a category attached, or 99.5%. Sun Pharmaceutical Industries Inc. accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest.

$2,412in general payments, 2019–2025

Across 2 payments — averaging $1205.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • Stryker$13
$1,247,088in research payments, 2019–2025

Across 5 payments — averaging $249,418 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.2M

What the payments were for

  • Speaking & faculty fees$2,39999%
  • Food & beverage$131%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sun Pharmaceutical Industries Inc.1$2,399
Stryker1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,412 in reported general payments places this provider in the 55th percentile of 114 pediatric hematology-oncology providers in Massachusetts.

See all pediatric hematology-oncology providers in Massachusetts

Other pediatric hematology-oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →